Merus (MRUS)
(Delayed Data from NSDQ)
$54.32 USD
-0.38 (-0.69%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $54.23 -0.09 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
MRUS 54.32 -0.38(-0.69%)
Will MRUS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRUS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRUS
Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
MRUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
Other News for MRUS
Merus announces first patient dosed in LiGeR-HN2 trial
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
Buy Rating Affirmed for Merus on Strong Potential of Lead Asset Petosemtamab in Combination and Second-Line Therapies
Merus price target raised by $23 at Citi, here's why